SUPPLEMENT
Q4 2023 — Other Financial Disclosures
Q4 2023PDF · 17 pages571 KB
Table 1: Sales by Segment 1 Table 2: Sales by Geographic Area 2 Table 3: Sales of Key Products/Franchises 3 - 7 Table 3a: Supplemental Sales Reconciliation 8 Table 4: Condensed Consolidated Statement of Earnings - QTD 9 Table 5: Condensed Consolidated Statement of Earnings - YTD 10 Table 6: Non-GAAP Adjusted Operational Sales Growth - QTD 11 Table 7: Non-GAAP Adjusted Operational Sales Growth - YTD 12 Table 8: Non-GAAP Adjusted Net Earnings 13 Table 9: Non-GAAP IBT and R&D Expense by Segment - QTD 14 Table 10: Non-GAAP IBT and R&D Expense by Segment - YTD 15 Table 11: Non-GAAP P&L Reconciliation 16 Fourth Quarter 2023 Other Financial Disclosures Table of Contents -- 1 of 17 -- Johnson & Johnson and Subsidiaries Supplementary Sales Data (Unaudited; Dollars in Millions) Percent Change 2023 2022 Total Operations Currency 2023 2022 Total Operations Currency Sales to customers by segment of business Innovative Medicine (1,2) U.S. 8,079 7,375 9.5 9.5 - 31,169 28,604 9.0 9.0 - International 5,643 5,788 (2.5) (3.1) 0.6 23,590 23,959 (1.5) (0.2) (1.3) 13,722 13,163 4.2 4.0 0.2 54,759 52,563 4.2 4.8 (0.6) Innovative Medicine excluding COVID-19 Vaccine (1,2) U.S. 8,079 7,375 9.5 9.5 - 31,169 28,484 9.4 9.4 - International 5,599 5,099 9.8 9.4 0.4 22,473 21,900 2.6 4.3 (1.7) 13,678 12,474 9.7 9.5 0.2 53,642 50,384 6.5 7.2 (0.7) MedTech U.S. 3,930 3,445 14.1 14.1 - 15,275 13,377 14.2 14.2 - International 3,743 3,331 12.4 12.8 (0.4) 15,125 14,050 7.7 10.6 (2.9) 7,673 6,776 13.3 13.4 (0.1) 30,400 27,427 10.8 12.4 (1.6) U.S. 12,009 10,820 11.0 11.0 - 46,444 41,981 10.6 10.6 - International 9,386 9,119 2.9 2.7 0.2 38,715 38,009 1.9 3.8 (1.9) Worldwide 21,395 19,939 7.3 7.2 0.1 85,159 79,990 6.5 7.4 (0.9) U.S. 12,009 10,820 11.0 11.0 - 46,444 41,861 10.9 10.9 - International 9,342 8,430 10.8 10.7 0.1 37,598 35,950 4.6 6.7 (2.1) Worldwide excluding COVID-19 Vaccine (1) 21,351 $ 19,250 10.9 % 10.9 0.0 84,042 $ 77,811 8.0 % 9.0 (1.0) Note: Percentages have been calculated using actual, non-rounded figures and, therefore, may not recalculate precisely. (1) Refer to supplemental sales reconciliation schedule (2) Previously referred to as Pharmaceutical FOURTH QUARTER TWELVE MONTHS Percent Change -- 2 of 17 -- Johnson & Johnson and Subsidiaries Supplementary Sales Data (Unaudited; Dollars in Millions) Percent Change 2023 2022 Total Operations Currency 2023 2022 Total Operations Currency Sales to customers by geographic area U.S. 12,009 $ 10,820 11.0 % 11.0 - 46,444 $ 41,981 10.6 % 10.6 - Europe 4,962 5,124 (3.2) (5.8) 2.6 20,410 20,664 (1.2) (2.2) 1.0 Western Hemisphere excluding U.S. 1,166 1,024 14.0 18.1 (4.1) 4,549 4,108 10.7 15.8 (5.1) Asia-Pacific, Africa 3,258 2,971 9.7 12.1 (2.4) 13,756 13,237 3.9 9.5 (5.6) International 9,386 9,119 2.9 2.7 0.2 38,715 38,009 1.9 3.8 (1.9) Worldwide 21,395 $ 19,939 7.3 % 7.2 0.1 85,159 $ 79,990 6.5 % 7.4 (0.9) Note: Percentages have been calculated using actual, non-rounded figures and, therefore, may not recalculate precisely. FOURTH QUARTER TWELVE MONTHS Percent Change -- 3 of 17 -- REPORTED SALES vs. PRIOR PERIOD ($MM) REPORTED SALES vs. PRIOR PERIOD ($MM) FOURTH QUARTER TWELVE MONTHS INNOVATIVE MEDICINE SEGMENT (2,3,4) 2023 2022 Reported Operational (1) Currency 2023 2022 Reported Operational (1) Currency IMMUNOLOGY US 3,033 $ 2,805 8.1% 8.1% - 11,539 $ 11,036 4.6% 4.6% - Intl 1,562 1,312 19.0% 17.7% 1.3% 6,513 5,899 10.4% 12.0% -1.6% WW 4,595 4,118 11.6% 11.2% 0.4% 18,052 16,935 6.6% 7.1% -0.5% REMICADE US 294 318 -7.4% -7.4% - 1,143 1,417 -19.3% -19.3% - US Exports (5) 35 41 -15.1% -15.1% - 147 204 -28.0% -28.0% - Intl 100 116 -13.4% -12.4% -1.0% 549 722 -23.9% -21.3% -2.6% WW 429 475 -9.6% -9.4% -0.2% 1,839 2,343 -21.5% -20.7% -0.8% SIMPONI / SIMPONI ARIA US 258 280 -7.8% -7.8% - 1,124 1,166 -3.6% -3.6% - Intl 244 220 10.1% 11.8% -1.7% 1,073 1,017 5.4% 9.3% -3.9% WW 502 501 0.1% 0.8% -0.7% 2,197 2,184 0.6% 2.4% -1.8% STELARA US 1,786 1,621 10.1% 10.1% - 6,966 6,388 9.0% 9.0% - Intl 967 764 26.4% 23.9% 2.5% 3,892 3,335 16.7% 17.4% -0.7% WW 2,753 2,386 15.3% 14.5% 0.8% 10,858 9,723 11.7% 11.9% -0.2% TREMFYA US 657 541 21.6% 21.6% - 2,147 1,844 16.5% 16.5% - Intl 252 211 19.4% 17.8% 1.6% 999 824 21.2% 22.4% -1.2% WW 910 752 21.0% 20.5% 0.5% 3,147 2,668 17.9% 18.3% -0.4% OTHER IMMUNOLOGY US 2 3 -22.8% -22.8% - 11 17 -33.8% -33.8% - Intl 0 0 - - - 0 0 - - - WW 2 3 -22.8% -22.8% - 11 17 -33.8% -33.8% - INFECTIOUS DISEASES US 353 414 -14.6% -14.6% - 1,500 1,680 -10.7% -10.7% - Intl 498 1,127 -55.8% -58.2% 2.4% 2,918 3,769 -22.6% -23.9% 1.3% WW 852 1,540 -44.7% -46.5% 1.8% 4,418 5,449 -18.9% -19.8% 0.9% COVID-19 VACCINE US 0 0 - - - 0 120 * * - Intl 44 689 -93.7% -95.2% 1.5% 1,117 2,059 -45.8% -47.2% 1.4% WW 44 689 -93.7% -95.2% 1.5% 1,117 2,179 -48.8% -50.1% 1.3% EDURANT / rilpivirine US 9 9 -12.4% -12.4% - 35 36 -3.7% -3.7% - Intl 299 281 6.4% 1.5% 4.9% 1,115 972 14.8% 12.1% 2.7% WW 307 290 5.8% 1.0% 4.8% 1,150 1,008 14.1% 11.5% 2.6% PREZISTA / PREZCOBIX / REZOLSTA / SYMTUZA US 341 398 -14.4% -14.4% - 1,446 1,494 -3.2% -3.2% - Intl 98 95 3.1% -0.8% 3.9% 408 449 -9.2% -10.4% 1.2% WW 439 493 -11.0% -11.8% 0.8% 1,854 1,943 -4.6% -4.9% 0.3% OTHER INFECTIOUS DISEASES US 4 6 -30.4% -30.4% - 19 30 -34.5% -34.5% - Intl 58 61 -5.6% -4.9% -0.7% 278 289 -3.8% -0.4% -3.4% WW 62 67 -7.8% -7.1% -0.7% 297 318 -6.7% -3.6% -3.1% % Change % Change -- 4 of 17 -- REPORTED SALES vs. PRIOR PERIOD ($MM) REPORTED SALES vs. PRIOR PERIOD ($MM) FOURTH QUARTER TWELVE MONTHS 2023 2022 Reported Operational (1) Currency 2023 2022 Reported Operational (1) Currency NEUROSCIENCE US 1,022 912 12.1% 12.1% - 4,065 3,570 13.9% 13.9% - Intl 780 825 -5.5% -2.0% -3.5% 3,076 3,323 -7.5% -3.7% -3.8% WW 1,801 1,737 3.7% 5.4% -1.7% 7,140 6,893 3.6% 5.4% -1.8% CONCERTA / Methylphenidate US 39 37 5.7% 5.7% - 230 151 52.5% 52.5% - Intl 142 131 7.9% 9.2% -1.3% 554 493 12.2% 16.4% -4.2% WW 180 168 7.4% 8.5% -1.1% 783 644 21.6% 24.9% -3.3% INVEGA SUSTENNA / XEPLION / INVEGA TRINZA / TREVICTA US 733 678 8.0% 8.0% - 2,897 2,714 6.7% 6.7% - Intl 278 329 -15.5% -15.7% 0.2% 1,218 1,426 -14.6% -12.8% -1.8% WW 1,011 1,008 0.3% 0.3% 0.0% 4,115 4,140 -0.6% 0.0% -0.6% SPRAVATO US 180 105 72.3% 72.3% - 589 328 79.7% 79.7% - Intl 26 14 87.1% 83.4% 3.7% 100 46 * * * WW 206 119 74.1% 73.6% 0.5% 689 374 84.1% 84.0% 0.1% OTHER NEUROSCIENCE US 71 91 -23.0% -23.0% - 349 376 -7.3% -7.3% - Intl 334 351 -5.0% 3.2% -8.2% 1,204 1,358 -11.3% -5.4% -5.9% WW 404 442 -8.7% -2.3% -6.4% 1,553 1,734 -10.4% -5.9% -4.5% ONCOLOGY US 2,285 1,857 23.0% 23.0% - 8,462 6,930 22.1% 22.1% - Intl 2,334 2,069 12.8% 12.0% 0.8% 9,199 9,052 1.6% 2.9% -1.3% WW 4,618 3,927 17.6% 17.2% 0.4% 17,661 15,983 10.5% 11.2% -0.7% CARVYKTI US 145 54 * * - 469 133 * * - Intl 13 - * * - 30 - * * - WW 159 54 * * 500 133 * * * DARZALEX US 1,395 1,139 22.5% 22.5% - 5,277 4,210 25.4% 25.4% - Intl 1,155 944 22.3% 21.8% 0.5% 4,467 3,767 18.6% 20.2% -1.6% WW 2,550 2,083 22.4% 22.2% 0.2% 9,744 7,977 22.2% 22.9% -0.7% ERLEADA US 287 275 4.4% 4.4% - 1,065 968 10.0% 10.0% - Intl 361 266 35.6% 34.0% 1.6% 1,322 913 44.8% 46.0% -1.2% WW 647 541 19.8% 19.0% 0.8% 2,387 1,881 26.9% 27.5% -0.6% IMBRUVICA US 255 318 -19.8% -19.8% - 1,051 1,390 -24.4% -24.4% - Intl 533 547 -2.6% -3.8% 1.2% 2,214 2,394 -7.5% -6.7% -0.8% WW 788 866 -8.9% -9.7% 0.8% 3,264 3,784 -13.7% -13.2% -0.5% ZYTIGA / abiraterone acetate US 9 20 -52.0% -52.0% - 50 74 -32.1% -32.1% - Intl 191 250 -23.6% -23.2% -0.4% 837 1,696 -50.7% -49.1% -1.6% WW 201 270 -25.6% -25.3% -0.3% 887 1,770 -49.9% -48.4% -1.5% OTHER ONCOLOGY US 192 52 * * - 549 156 * * - Intl 82 63 32.2% 28.4% 3.8% 330 283 16.9% 17.0% -0.1% WW 274 114 * * * 879 438 * * * % Change % Change -- 5 of 17 -- REPORTED SALES vs. PRIOR PERIOD ($MM) REPORTED SALES vs. PRIOR PERIOD ($MM) FOURTH QUARTER TWELVE MONTHS 2023 2022 Reported Operational (1) Currency 2023 2022 Reported Operational (1) Currency PULMONARY HYPERTENSION US 733 610 20.2% 20.2% - 2,697 2,346 15.0% 15.0% - Intl 282 261 8.6% 10.9% -2.3% 1,117 1,071 4.3% 8.3% -4.0% WW 1,017 870 16.7% 17.4% -0.7% 3,815 3,417 11.6% 12.9% -1.3% OPSUMIT US 368 305 20.5% 20.5% - 1,292 1,132 14.1% 14.1% - Intl 169 156 7.9% 8.3% -0.4% 681 651 4.6% 7.2% -2.6% WW 536 461 16.2% 16.3% -0.1% 1,973 1,783 10.6% 11.6% -1.0% UPTRAVI US 348 280 24.3% 24.3% - 1,326 1,104 20.1% 20.1% - Intl 70 56 26.4% 31.4% -5.0% 255 218 17.3% 21.8% -4.5% WW 419 336 24.6% 25.4% -0.8% 1,582 1,322 19.7% 20.4% -0.7% OTHER PULMONARY HYPERTENSION US 18 24 -29.4% -29.4% - 79 110 -28.6% -28.6% - Intl 45 48 -9.7% -3.9% -5.8% 182 202 -10.3% -2.9% -7.4% WW 61 73 -16.2% -12.4% -3.8% 260 313 -16.7% -12.0% -4.7% CARDIOVASCULAR / METABOLISM / OTHER US 652 776 -15.9% -15.9% - 2,906 3,042 -4.5% -4.5% - Intl 185 194 -4.7% -6.7% 2.0% 765 845 -9.4% -9.1% -0.3% WW 837 971 -13.7% -14.1% 0.4% 3,671 3,887 -5.5% -5.5% 0.0% XARELTO US 525 667 -21.2% -21.2% - 2,365 2,473 -4.4% -4.4% - Intl - - - - - - - - - - WW 525 667 -21.2% -21.2% - 2,365 2,473 -4.4% -4.4% - OTHER US 127 110 15.9% 15.9% - 541 569 -5.0% -5.0% - Intl 185 194 -4.7% -6.7% 2.0% 765 845 -9.4% -9.1% -0.3% WW 312 304 2.8% 1.5% 1.3% 1,306 1,414 -7.6% -7.4% -0.2% TOTAL INNOVATIVE MEDICINE US 8,079 7,375 9.5% 9.5% - 31,169 28,604 9.0% 9.0% - Intl 5,643 5,788 -2.5% -3.1% 0.6% 23,590 23,959 -1.5% -0.2% -1.3% WW 13,722 $ 13,163 4.2% 4.0% 0.2% 54,759 $ 52,563 4.2% 4.8% -0.6% See footnotes at end of schedule % Change % Change -- 6 of 17 -- REPORTED SALES vs. PRIOR PERIOD ($MM) REPORTED SALES vs. PRIOR PERIOD ($MM) FOURTH QUARTER TWELVE MONTHS MEDTECH SEGMENT (2,3) 2023 2022 Reported Operational (1) Currency 2023 2022 Reported Operational (1) Currency INTERVENTIONAL SOLUTIONS US 971 $ 603 61.0% 61.0% - 3,633 $ 2,169 67.5% 67.5% - Intl 698 495 40.8% 41.7% -0.9% 2,717 2,131 27.5% 31.7% -4.2% WW 1,669 1,098 51.9% 52.3% -0.4% 6,350 4,300 47.7% 49.8% -2.1% ELECTROPHYSIOLOGY US 667 547 22.0% 22.0% - 2,458 2,036 20.7% 20.7% - Intl 572 447 28.0% 29.0% -1.0% 2,230 1,901 17.3% 21.5% -4.2% WW 1,239 994 24.7% 25.2% -0.5% 4,688 3,937 19.1% 21.1% -2.0% ABIOMED US 276 31 * * - 1,066 31 * * - Intl 64 - * * - 240 - * * - WW 340 31 * * - 1,306 31 * * - OTHER INTERVENTIONAL SOLUTIONS US 28 25 8.8% 8.8% - 109 102 6.7% 6.7% - Intl 61 48 26.5% 27.1% -0.6% 247 230 7.3% 11.4% -4.1% WW 89 73 20.4% 20.7% -0.3% 356 332 7.1% 9.9% -2.8% ORTHOPAEDICS US 1,425 1,385 2.9% 2.9% - 5,525 5,321 3.8% 3.8% - Intl 843 763 10.5% 8.8% 1.7% 3,417 3,267 4.6% 5.8% -1.2% WW 2,268 2,148 5.6% 5.0% 0.6% 8,942 8,587 4.1% 4.6% -0.5% HIPS US 266 250 6.3% 6.3% - 996 943 5.6% 5.6% - Intl 132 135 -2.0% -3.9% 1.9% 564 571 -1.2% -0.1% -1.1% WW 398 385 3.4% 2.7% 0.7% 1,560 1,514 3.0% 3.5% -0.5% KNEES US 242 231 4.5% 4.5% - 896 851 5.3% 5.3% - Intl 144 122 18.1% 15.6% 2.5% 559 508 10.2% 11.1% -0.9% WW 387 354 9.2% 8.4% 0.8% 1,456 1,359 7.1% 7.5% -0.4% TRAUMA US 487 470 3.6% 3.6% - 1,949 1,882 3.6% 3.6% - Intl 255 240 5.9% 4.1% 1.8% 1,030 989 4.1% 4.8% -0.7% WW 741 710 4.4% 3.8% 0.6% 2,979 2,871 3.8% 4.0% -0.2% SPINE, SPORTS & OTHER US 430 434 -0.7% -0.7% - 1,684 1,645 2.4% 2.4% - Intl 311 265 17.5% 16.5% 1.0% 1,263 1,198 5.4% 7.3% -1.9% WW 742 699 6.2% 5.8% 0.4% 2,947 2,843 3.7% 4.5% -0.8% % Change % Change -- 7 of 17 -- REPORTED SALES vs. PRIOR PERIOD ($MM) REPORTED SALES vs. PRIOR PERIOD ($MM) FOURTH QUARTER TWELVE MONTHS 2023 2022 Reported Operational (1) Currency 2023 2022 Reported Operational (1) Currency SURGERY US 1,047 1,000 4.6% 4.6% - 4,031 3,897 3.4% 3.4% - Intl 1,484 1,383 7.2% 7.8% -0.6% 6,006 5,793 3.7% 7.0% -3.3% WW 2,530 2,384 6.1% 6.4% -0.3% 10,037 9,690 3.6% 5.5% -1.9% ADVANCED US 468 456 2.5% 2.5% - 1,833 1,784 2.8% 2.8% - Intl 698 653 7.0% 7.2% -0.2% 2,837 2,785 1.9% 5.1% -3.2% WW 1,167 1,109 5.1% 5.2% -0.1% 4,671 4,569 2.2% 4.2% -2.0% GENERAL US 579 544 6.4% 6.4% - 2,198 2,113 4.0% 4.0% - Intl 785 731 7.4% 8.3% -0.9% 3,168 3,008 5.3% 8.7% -3.4% WW 1,364 1,275 7.0% 7.5% -0.5% 5,366 5,121 4.8% 6.8% -2.0% VISION US 487 456 6.8% 6.8% - 2,086 1,990 4.8% 4.8% - Intl 721 689 4.6% 6.4% -1.8% 2,986 2,859 4.5% 7.9% -3.4% WW 1,208 1,145 5.5% 6.6% -1.1% 5,072 4,849 4.6% 6.6% -2.0% CONTACT LENSES / OTHER US 374 343 8.9% 8.9% - 1,626 1,522 6.8% 6.8% - Intl 508 489 4.2% 7.2% -3.0% 2,076 2,022 2.7% 7.0% -4.3% WW 882 831 6.1% 7.9% -1.8% 3,702 3,543 4.5% 6.9% -2.4% SURGICAL US 114 113 0.4% 0.4% - 460 468 -1.8% -1.8% - Intl 212 200 5.6% 4.7% 0.9% 910 837 8.6% 10.0% -1.4% WW 326 314 3.7% 3.1% 0.6% 1,370 1,306 4.9% 5.8% -0.9% TOTAL MEDTECH US 3,930 3,445 14.1% 14.1% - 15,275 13,377 14.2% 14.2% - Intl 3,743 3,331 12.4% 12.8% -0.4% 15,125 14,050 7.7% 10.6% -2.9% WW 7,673 $ 6,776 13.3% 13.4% -0.1% 30,400 $ 27,427 10.8% 12.4% -1.6% * Percentage greater than 100% or not meaningful (1) Operational growth excludes the effect of translational currency (2) Unaudited (3) Certain prior year amounts have been reclassified to conform to current year product disclosures (4) Previously referred to as Pharmaceutical (5) Reported as U.S. sales % Change % Change Note: Columns and rows within tables may not add due to rounding. Percentages have been calculated using actual, non-rounded figures and, therefore, may not recalculate precisely -- 8 of 17 -- 2023 2022 Total Operations Currency 2023 2022 Total Operations Currency Innovative Medicine U.S. 8,079 $ 7,375 9.5 % 9.5 - 31,169 $ 28,604 9.0 % 9.0 - International 5,643 5,788 (2.5) (3.1) 0.6 23,590 23,959 (1.5) (0.2) (1.3) Worldwide 13,722 13,163 4.2 4.0 0.2 54,759 52,563 4.2 4.8 (0.6) COVID-19 Vaccine U.S. - - - - - - 120 * * - International 44 689 (93.7) (95.2) 1.5 1,117 2,059 (45.8) (47.2) 1.4 Worldwide 44 689 (93.7) (95.2) 1.5 1,117 2,179 (48.8) (50.1) 1.3 Innovative Medicine excluding COVID-19 Vaccine U.S. 8,079 7,375 9.5 9.5 - 31,169 28,484 9.4 9.4 - International 5,599 5,099 9.8 9.4 0.4 22,473 21,900 2.6 4.3 (1.7) Worldwide 13,678 12,474 9.7 9.5 0.2 53,642 50,384 6.5 7.2 (0.7) Worldwide U.S. 12,009 10,820 11.0 11.0 - 46,444 41,981 10.6 10.6 - International 9,386 9,119 2.9 2.7 0.2 38,715 38,009 1.9 3.8 (1.9) Worldwide 21,395 19,939 7.3 7.2 0.1 85,159 79,990 6.5 7.4 (0.9) COVID-19 Vaccine U.S. - - - - - - 120 * * - International 44 689 (93.7) (95.2) 1.5 1,117 2,059 (45.8) (47.2) 1.4 Worldwide 44 689 (93.7) (95.2) 1.5 1,117 2,179 (48.8) (50.1) 1.3 Worldwide U.S. 12,009 10,820 11.0 11.0 - 46,444 41,861 10.9 10.9 - International 9,342 8,430 10.8 10.7 0.1 37,598 35,950 4.6 6.7 (2.1) Worldwide excluding COVID-19 Vaccine 21,351 $ 19,250 10.9 % 10.9 - 84,042 $ 77,811 8.0 % 9.0 (1.0) Note: Columns and rows within tables may not add due to rounding * Percentage greater than 100% or not meaningful Supplemental Sales Reconciliation (Unaudited) (Dollars in Millions) FOURTH QUARTER TWELVE MONTHS Percent Change Percent Change -- 9 of 17 -- Johnson & Johnson and Subsidiaries Condensed Consolidated Statement of Earnings (Unaudited; in Millions Except Per Share Figures) Percent Percent Percent Increase Amount to Sales Amount to Sales (Decrease) Sales to customers 21,395 $ 100.0 19,939 $ 100.0 7.3 Cost of products sold 6,798 31.8 6,084 30.5 11.7 Gross Profit 14,597 68.2 13,855 69.5 5.4 Selling, marketing and administrative expenses 5,810 27.1 5,339 26.8 8.8 Research and development expense 4,480 20.9 3,710 18.6 20.8 In-process research and development impairments 58 0.3 173 0.8 Interest (income) expense, net (212) (1.0) (77) (0.4) Other (income) expense, net (421) (2.0) 795 4.0 Restructuring 56 0.3 75 0.4 Earnings before provision for taxes on income 4,826 22.6 3,840 19.3 25.7 Provision for taxes on income 694 3.3 613 3.1 13.2 Net earnings from Continuing Operations 4,132 $ 19.3 3,227 $ 16.2 28.0 Net earnings/(loss) from Discontinued Operations, net of tax (83) 293 Net earnings 4,049 $ 3,520 $ Net earnings per share (Diluted) from Continuing Operations 1.70 $ 1.22 $ 39.3 Net earnings/(loss) per share (Basic/Diluted) from Discontinued Operations* (0.03) $ 0.11 $ Average shares outstanding (Diluted) 2,430.7 2,650.1 Effective tax rate from Continuing Operations 14.4 % 16.0 % Adjusted earnings from Continuing Operations before provision for taxes and net earnings (1) Earnings before provision for taxes on income from Continuing Operations 6,237 $ 29.2 6,482 $ 32.5 (3.8) Net earnings from Continuing Operations 5,562 $ 26.0 5,432 $ 27.2 2.4 Net earnings per share (Diluted) from Continuing Operations 2.29 $ 2.05 $ 11.7 Effective tax rate from Continuing Operations 10.8 % 16.2 % * Basic shares of 2,407.2 are used to calculate loss per share in the fourth quarter of 2023 as use of diluted shares when in a loss position would be anti-dilutive. (1) See Reconciliation of Non-GAAP Financial Measures. FOURTH QUARTER 2023 2022 -- 10 of 17 -- Johnson & Johnson and Subsidiaries Condensed Consolidated Statement of Earnings (Unaudited; in Millions Except Per Share Figures) Percent Percent Percent Increase Amount to Sales Amount to Sales (Decrease) Sales to customers 85,159 $ 100.0 79,990 $ 100.0 6.5 Cost of products sold 26,553 31.2 24,596 30.7 8.0 Gross Profit 58,606 68.8 55,394 69.3 5.8 Selling, marketing and administrative expenses 21,512 25.2 20,246 25.3 6.3 Research and development expense 15,085 17.7 14,135 17.7 6.7 In-process research and development impairments 313 0.4 783 1.0 Interest (income) expense, net (489) (0.6) (214) (0.3) Other (income) expense, net 6,634 7.8 810 1.0 Restructuring 489 0.6 275 0.4 Earnings before provision for taxes on income 15,062 17.7 19,359 24.2 (22.2) Provision for taxes on income 1,736 2.1 2,989 3.7 (41.9) Net earnings from Continuing Operations 13,326 $ 15.6 16,370 $ 20.5 (18.6) Net earnings from Discontinued Operations, net of tax 21,827 1,571 Net earnings 35,153 $ 17,941 $ Net earnings per share (Diluted) from Continuing Operations 5.20 $ 6.14 $ (15.3) Net earnings per share (Diluted) from Discontinued Operations 8.52 $ 0.59 $ Average shares outstanding (Diluted) 2,560.4 2,663.9 Effective tax rate from Continuing Operations 11.5 % 15.4 % Adjusted earnings from continuing operations before provision for taxes and net earnings (1) Earnings before provision for taxes on income from Continuing Operations 29,811 $ 35.0 27,973 $ 35.0 6.6 Net earnings from Continuing Operations 25,409 $ 29.8 23,796 $ 29.7 6.8 Net earnings per share (Diluted) from Continuing Operations 9.92 $ 8.93 $ 11.1 Effective tax rate from Continuing Operations 14.8 % 14.9 % (1) See Reconciliation of Non-GAAP Financial Measures. TWELVE MONTHS 2023 2022 -- 11 of 17 -- Johnson & Johnson and Subsidiaries Reconciliation of Non-GAAP Financial Measure Innovative Medicine MedTech Total WW As Reported 4.2% 13.3% 7.3% U.S. 9.5% 14.1% 11.0% International (2.5)% 12.4% 2.9% WW Currency 0.2 (0.1) 0.1 U.S. - - - International 0.6 (0.4) 0.2 WW Operational 4.0% 13.4% 7.2% U.S. 9.5% 14.1% 11.0% International (3.1)% 12.8% 2.7% Abiomed (4.5) (1.6) U.S. (7.2) (2.3) International (1.9) (0.7) All Other Acquisitions and Divestitures 0.0 0.2 0.1 U.S. 0.0 0.3 0.1 International 0.1 0.1 0.1 WW Adjusted Operational 4.0% 9.1% 5.7% U.S. 9.5% 7.2% 8.8% International (3.0)% 11.0% 2.1% Adjusted Operational Sales Growth FOURTH QUARTER 2023 ACTUAL vs. 2022 ACTUAL Segments Note: Percentages are based on actual, non-rounded figures and may not sum -- 12 of 17 -- Johnson & Johnson and Subsidiaries Reconciliation of Non-GAAP Financial Measure Innovative Medicine MedTech Total WW As Reported 4.2% 10.8% 6.5% U.S. 9.0% 14.2% 10.6% International (1.5)% 7.7% 1.9% WW Currency (0.6) (1.6) (0.9) U.S. - - - International (1.3) (2.9) (1.9) WW Operational 4.8% 12.4% 7.4% U.S. 9.0% 14.2% 10.6% International (0.2)% 10.6% 3.8% Abiomed (4.7) (1.6) U.S. (7.7) (2.5) International (1.7) (0.6) All Other Acquisitions and Divestitures 0.1 0.1 0.1 U.S. 0.0 0.1 0.1 International 0.2 0.1 0.2 WW Adjusted Operational 4.9% 7.8% 5.9% U.S. 9.0% 6.6% 8.2% International 0.0% 9.0% 3.4% Adjusted Operational Sales Growth TWELVE MONTHS 2023 ACTUAL vs. 2022 ACTUAL Segments Note: Percentages are based on actual, non-rounded figures and may not sum -- 13 of 17 -- Johnson & Johnson and Subsidiaries Reconciliation of Non-GAAP Financial Measures (Dollars in Millions Except Per Share Data) 2023 2022 2023 2022 Net Earnings from Continuing Operations, after tax- as reported $4,132 $3,227 $13,326 $16,370 Pre-tax Adjustments Litigation related 166 262 7,152 866 Intangible Asset Amortization expense 1,148 977 4,532 3,944 COVID-19 Vaccine related costs 1 10 821 663 1,474 Restructuring related 2 139 119 798 372 Medical Device Regulation 3 88 88 311 296 Acquisition, integration and divestiture related 237 196 339 196 (Gains)/losses on securities (435) 6 641 690 IPR&D impairments 58 173 313 783 Other - - - (7) Tax Adjustments Tax impact on special item adjustments 4 75 (394) (2,694) (1,294) Tax legislation and other tax related (56) (43) 28 106 Adjusted Net Earnings from Continuing Operations, after tax $5,562 $5,432 $25,409 $23,796 Average shares outstanding (Diluted) 2,430.7 2,650.1 2,560.4 2,663.9 Adjusted net earnings per share from Continuing Operations (Diluted) $2.29 $2.05 $9.92 $8.93 Operational adjusted net earnings per share from Continuing Operations (Diluted) $2.28 $9.89 Notes: 1 2 3 4 The tax impact related to special item adjustments reflects the current and deferred income taxes associated with the above pre-tax special items in arriving at adjusted earnings. Fourth Quarter Twelve Months Ended COVID-19 Vaccine related costs include remaining commitments and obligations, including external manufacturing network exit costs and required clinical trial expenses, associated with the Company's completion of its COVID-19 vaccine contractual commitments. In fiscal 2023, the company completed a prioritization of its research and development (R&D) investment within the Innovative Medicine segment to focus on the most promising medicines with the greatest benefit to patients. This resulted in the exit of certain programs within therapeutic areas. The R&D program exits are primarily in infectious diseases and vaccines including the discontinuation of its respiratory syncytial virus (RSV) adult vaccine program, hepatitis and HIV development. The restructuring expenses of $55 million in the quarter ($479 million Q4 YTD) include the termination of partnered and non-partnered program costs and asset impairments. In fiscal 2023, the company initiated a restructuring program of its Orthopaedics franchise within the MedTech segment to streamline operations by exiting certain markets, product lines and distribution network arrangements. The restructuring expenses of $84 million in the quarter ($319 million Q4 YTD) primarily includes inventory and instrument reserves related to the market and product exits. European Medical Device Regulation (MDR) costs represent one-time compliance costs for the Company’s previously registered products. MDR is a replacement of the existing European Medical Devices Directive regulatory framework, and manufacturers of currently marketed medical devices were required to comply with EU MDR beginning in May 2021. The Company considers the adoption of EU MDR to be a significant one-time regulatory change and is not indicative of on-going operations. The Company has excluded only external third-party regulatory and consulting costs from its MedTech operating segments' measures of profit and loss used for making operating decisions and assessing performance which is expected to be completed during 2024. -- 14 of 17 -- Johnson & Johnson and Subsidiaries Reconciliation of Non-GAAP Financial Measures 2023 2022 2023 2022 2023 2022 2023 2022 Reported Income Before Tax by Segment From Continuing Operations $ 4,238 3,223 404 806 184 (189) 4,826 3,840 % to Sales 30.9% 24.5% 5.3% 11.9% 0.9% -0.9% 22.6% 19.3% Intangible asset amortization expense 747 717 401 260 - - 1,148 977 In-process research and development impairments - 173 58 - - - 58 173 Litigation related 17 76 149 136 - 50 166 262 Loss/(gain) on securities (112) 23 (59) (17) (264) - (435) 6 Restructuring related 55 31 84 88 - - 139 119 Acquisition, integration and divestiture related 175 (104) 62 300 - - 237 196 Medical Device Regulation - - 88 88 - - 88 88 COVID-19 Vaccine related costs 10 821 - - - - 10 821 Adjusted Income Before Tax by Segment From Continuing Operations $ 5,130 4,960 1,187 1,661 (80) (139) 6,237 6,482 % to Sales 37.4% 37.7% 15.5% 24.5% -0.4% -0.7% 29.2% 32.5% *Estimated as of 1/23/2024 As Reported Research and Development Expense $ 3,357 3,070 1,123 640 4,480 3,710 % to Sales 24.5% 23.3% 14.6% 9.4% 20.9% 18.6% Q4 QTD - Income Before Tax* and Research & Development Expense by Segment Dollars in Millions Innovative Medicine MedTech Unallocated Worldwide Total -- 15 of 17 -- Johnson & Johnson and Subsidiaries Reconciliation of Non-GAAP Financial Measures 2023 2022 2023 2022 2023 2022 2023 2022 Reported Income Before Tax by Segment From Continuing Operations $ 18,246 15,647 4,669 4,447 (7,853) (735) 15,062 19,359 % to Sales 33.3% 29.8% 15.4% 16.2% -9.2% -0.9% 17.7% 24.2% Intangible asset amortization expense 2,983 2,911 1,549 1,033 - - 4,532 3,944 In-process research and development impairments 206 783 107 - - - 313 783 Litigation related (108) 104 190 612 7,070 150 7,152 866 Loss/(gain) on securities 362 696 (102) (6) 381 - 641 690 Restructuring related 479 63 319 309 - - 798 372 Acquisition, integration and divestiture related 175 (104) 164 300 - - 339 196 Medical Device Regulation - - 311 296 - - 311 296 COVID-19 Vaccine related costs 663 1,474 - - - - 663 1,474 Other - - - - - (7) - (7) Adjusted Income Before Tax by Segment From Continuing Operations $ 23,006 21,574 7,207 6,991 (402) (592) 29,811 27,973 % to Sales 42.0% 41.0% 23.7% 25.5% -0.5% -0.7% 35.0% 35.0% *Estimated as of 1/23/2024 As Reported Research and Development Expense $ 11,963 11,642 3,122 2,493 15,085 14,135 % to Sales 21.8% 22.1% 10.3% 9.1% 17.7% 17.7% Q4 YTD - Income Before Tax* and Research & Development Expense by Segment Dollars in Millions Innovative Medicine MedTech Unallocated Worldwide Total -- 16 of 17 -- Fourth Quarter Dec. 31, 2023 GAAP Intangible asset amortization Litigation related Restructuring related Medical Device Regulation Other Fourth Quarter Dec. 31, 2023 Non-GAAP Cost of products sold 6,798 $ (1,131) (83) (42) (12) - - 5,530 Selling, marketing and admin expenses 5,810 (8) 5,802 Research and development expense 4,480 (16) (38) (1) 4,425 Other (Income) / Expense (421) (17) (166) - (221) 435 3 - (387) In-process research and development impairments 58 (58) - Restructuring 56 (56) - Provision for taxes on income 694 175 (134) 13 16 30 (191) 16 - 56 - 675 Net Earnings from Continuing Operations 4,132 973 300 45 123 207 (244) 72 10 (56) - 5,562 Fourth Quarter Jan. 1, 2023 GAAP Intangible asset amortization Litigation related Restructuring related Medical Device Regulation Other Fourth Quarter Jan. 1, 2023 Non-GAAP Cost of products sold 6,084 $ (977) (25) (33) (160) - - 4,889 Selling, marketing and admin expenses 5,339 (9) 5,330 Research and development expense 3,710 - (46) (114) 3,550 Other (Income) / Expense 795 - (262) (19) (196) (6) (547) - (235) In-process research and development impairments 173 (173) - Restructuring 75 (75) - Provision for taxes on income 613 148 (36) 40 19 5 2 17 199 43 - 1,050 Net Earnings from Continuing Operations 3,227 829 298 133 100 191 4 71 622 (43) - 5,432 Twelve Months Dec. 31, 2023 GAAP Intangible asset amortization Litigation related Restructuring related Medical Device Regulation Other Twelve Months Dec. 31, 2023 Non-GAAP Cost of products sold 26,553 $ (4,511) (309) (133) (189) 21,411 Selling, marketing and admin expenses 21,512 (29) - 21,483 Research and development expense 15,085 (32) (149) (99) 14,805 Other (Income) / Expense 6,634 (21) (7,152) - (307) (641) (375) - (1,862) In-process research and development impairments 313 (313) - - - - - Restructuring 489 (489) - Provision for taxes on income 1,736 707 1,505 70 157 52 (9) 57 155 (28) - 4,402 Net Earnings from Continuing Operations 13,326 3,825 5,647 243 641 287 650 254 508 28 - 25,409 Twelve Months Jan. 1, 2023 GAAP Intangible asset amortization Litigation related Restructuring related Medical Device Regulation Other Twelve Months Jan. 1, 2023 Non-GAAP Cost of products sold 24,596 $ (3,944) (62) (109) (456) 20,025 Selling, marketing and admin expenses 20,246 (28) 20,218 Research and development expense 14,135 - (159) (304) 13,672 Other (Income) / Expense 810 - (866) (35) (196) (690) (714) 7 (1,684) In-process research and development impairments 783 (783) - - Restructuring 275 (275) - Provision for taxes on income 2,989 590 (125) 178 66 5 166 56 360 (106) (2) 4,177 Net Earnings from Continuing Operations 16,370 3,354 991 605 306 191 524 240 1,114 106 (5) 23,796 Johnson & Johnson and Subsidiaries GAAP to Non-GAAP Reconciliation $ in Millions Quarter to Date In-process research and development impairments Acquisition, integration and divestiture related (Loss)/gain on securities COVID-19 Vaccine Related Costs Tax legislation and other tax related In-process research and development impairments Acquisition, integration and divestiture related (Loss)/gain on securities COVID-19 Vaccine Related Costs Tax legislation and other tax related Year to Date In-process research and development impairments Acquisition, integration and divestiture related (Loss)/gain on securities COVID-19 Vaccine Related Costs Tax legislation and other tax related In-process research and development impairments Acquisition, integration and divestiture related (Loss)/gain on securities COVID-19 Vaccine Related Costs Tax legislation and other tax related -- 17 of 17 --